Study showed no clinically significant change in blood levels for pitavastatin or protease inhibitor combination darunavir/ritonavir when co-administered (Logo: http ...
Eli Lilly announced its cardiovascular sales force will co-promote Japan-based Kowa Pharmaceuticals' newly approved cholesterol-lowering drug Livalo in the U.S. The marketing deal could prove a costly ...
Livalo (pitavastatin) is a brand-name oral tablet prescribed to lower cholesterol levels in certain adults and children. Livalo has interactions with some other drugs. Examples include other ...
PREVAIL U.S. primary and secondary lipid endpoints and lipoprotein particle analysis presented at the National Lipid Association Scientific Sessions SCOTTSDALE, Ariz., May 31, 2012 /PRNewswire via ...
The approval was based on a double blind, placebo controlled, 12-week trial in 82 pediatric patients (8-16 years old) with HeFH, fasting LDL-C ≥190mg/dL or LDL-C ≥160mg/dL with an additional ...
First-ever meta-analysis of pitavastatin confirms no significant adverse effect compared with placebo or other statins on fasting blood glucose, HbA1c, or new-onset diabetes MONTGOMERY, Ala., Kowa ...
Studies have shown that patients living with HIV infection have increased cardiovascular disease risk factors, including dyslipidemia and glucose abnormalities. 2 "We are pleased with the results of ...
Please provide your email address to receive an email when new articles are posted on . Taiwanese adults with poorly controlled type 2 diabetes who were statin-naive or prescribed atorvastatin for ...
Livalo approved for primary hypercholesterolemia and combined dyslipidemia Livalo (pitavastatin tablets, from Kowa Pharmaceuticals) has been FDA approved for the primary treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results